Current role of radionuclide imaging in differentiated thyroid cancer

Abstract Nuclear medicine plays an integral role in the management of differentiated thyroid cancer. This editorial aims to provide a summary of the current role of radionuclide imaging, including whole body iodine scan and fluorodeoxyglucose (FDG)-positron emission tomography (PET), in the diagnostic work-up and follow-up of patients with thyroid cancer.

[1]  W. Oyen,et al.  Utility of fluorodeoxyglucose-PET in patients with differentiated thyroid carcinoma , 2008, Nuclear medicine communications.

[2]  Youngho Seo,et al.  Technological development and advances in single-photon emission computed tomography/computed tomography. , 2008, Seminars in nuclear medicine.

[3]  A. Iagaru,et al.  F-18 FDG PET/CT in the Management of Thyroid Cancer , 2007, Clinical nuclear medicine.

[4]  E. Silberstein.  Comparison of Outcomes After 123I Versus 131I Preablation Imaging Before Radioiodine Ablation in Differentiated Thyroid Carcinoma , 2007, Journal of Nuclear Medicine.

[5]  Tae Yong Kim,et al.  18F-fluorodeoxyglucose positron emission tomography does not predict malignancy in thyroid nodules cytologically diagnosed as follicular neoplasm. , 2007, The Journal of clinical endocrinology and metabolism.

[6]  E. Silberstein.  Comparison of Outcomes After 123 I Versus 131 I Preablation Imaging Before Radioiodine Ablation in Differentiated Thyroid Carcinoma , 2007 .

[7]  H. Gallowitsch,et al.  Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality? , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  M. Pelizzo,et al.  The role of sentinel lymph node biopsy in patients with differentiated thyroid carcinoma. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[9]  W. Wiersinga,et al.  European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. , 2006, European journal of endocrinology.

[10]  W. Oyen,et al.  18F-FDG PET reduces unnecessary hemithyroidectomies for thyroid nodules with inconclusive cytologic results. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  E. Wardelmann,et al.  Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  Gerard M Doherty,et al.  Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2006, Thyroid : official journal of the American Thyroid Association.

[13]  Mithat Gonen,et al.  Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. , 2006, The Journal of clinical endocrinology and metabolism.

[14]  A. Soricelli,et al.  Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  P. Hasselgren,et al.  Preoperative evaluation of thyroid nodules with 18FDG-PET/CT. , 2005, Surgery.

[16]  David Goldenberg,et al.  The Role of Positron Emission Tomography/Computed Tomography in the Management of Recurrent Papillary Thyroid Carcinoma , 2005, The Laryngoscope.

[17]  Pedro Wesley Souza Do Rosário,et al.  Post I-131 Therapy Scanning in Patients With Thyroid Carcinoma Metastases: An Unnecessary Cost or a Relevant Contribution? , 2004, Clinical nuclear medicine.

[18]  S. Mandel,et al.  A 64-year-old woman with a thyroid nodule. , 2004, JAMA.

[19]  H. Amthauer,et al.  Impact of SPECT and integrated low-dose CT after radioiodine therapy on the management of patients with thyroid carcinoma , 2004, Nuclear medicine communications.

[20]  V. Cuccurullo,et al.  Nuclear medicine in diagnosis, staging and follow-up of thyroid cancer. , 2004, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[21]  L. Hurtado-López,et al.  Combined use of fine-needle aspiration biopsy, MIBI scans and frozen section biopsy offers the best diagnostic accuracy in the assessment of the hypofunctioning solitary thyroid nodule , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  G. Cook,et al.  Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging. , 2004, Seminars in nuclear medicine.

[23]  M. Luster,et al.  Impact of 131I diagnostic activities on the biokinetics of thyroid remnants. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  L. Duntas,et al.  Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. , 2004, European journal of endocrinology.

[25]  P. Mikosch,et al.  Evaluation of thyroid nodules with technetium-99m tetrofosmin dual-phase scintigraphy , 1997, European Journal of Nuclear Medicine.

[26]  L. Hegedüs,et al.  Clinical practice. The thyroid nodule. , 2004, The New England journal of medicine.

[27]  H. Stettner,et al.  Fluorine-18-fluorodeoxyglucose positron emission tomography in the preoperative assessment of thyroid nodules in an endemic goiter area. , 2003, Surgery.

[28]  Mary C Frates,et al.  Assessment of nondiagnostic ultrasound-guided fine needle aspirations of thyroid nodules. , 2002, The Journal of clinical endocrinology and metabolism.

[29]  C. Harmer.  British Thyroid Association: Guidelines for the management of Thyroid Cancer in Adults. , 2002 .

[30]  A. Engel,et al.  The new technology of combined transmission and emission tomography in evaluation of endocrine neoplasms. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  A. Alavi,et al.  Superiority of Iodine-123 Compared with Iodine-131 Scanning for Thyroid Remnants in Patients with Differentiated Thyroid Cancer , 2001, Clinical nuclear medicine.

[32]  R. Buchert,et al.  Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  L. Fig,et al.  Artifacts, anatomical and physiological variants, and unrelated diseases that might cause false-positive whole-body 131-I scans in patients with thyroid cancer. , 2000, Seminars in nuclear medicine.

[34]  P. Mikosch,et al.  Value of ultrasound-guided fine-needle aspiration biopsy of thyroid nodules in an endemic goitre area , 2000, European Journal of Nuclear Medicine.

[35]  E. Baudin,et al.  Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? , 2000, The Journal of clinical endocrinology and metabolism.

[36]  K. Spicer,et al.  The usefulness of iodine-123 whole-body scans in evaluating thyroid carcinoma and metastases. , 1999, Journal of nuclear medicine technology.

[37]  O. Schober,et al.  Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study , 1999, European Journal of Nuclear Medicine.

[38]  E. Mezosi,et al.  The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the differential diagnosis of cold thyroid nodules , 1999, European Journal of Nuclear Medicine.

[39]  Scott T. Grafton,et al.  Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. , 1999, Thyroid : official journal of the American Thyroid Association.

[40]  F. F. Melacrinis,et al.  Role of initial iodine-131 whole-body scan and serum thyroglobulin in differentiated thyroid carcinoma metastases. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[41]  R B Jeffrey,et al.  Ultrasound-guided fine-needle aspiration biopsy of thyroid masses. , 1998, Thyroid : official journal of the American Thyroid Association.

[42]  N. Sadato,et al.  Fluorine-18-fluorodeoxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors. , 1998, Journal of Nuclear Medicine.

[43]  J. Clerc,et al.  Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma , 1998, European Journal of Nuclear Medicine.

[44]  P. Giraud,et al.  Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[45]  J. Reynolds.  Percent 131I uptake and post-therapy 131I scans: their role in the management of thyroid cancer. , 1997, Thyroid : official journal of the American Thyroid Association.

[46]  P. Mikosch,et al.  Technetium-99m-MIBI scintigraphy of thyroid nodules in an endemic goiter area. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[47]  J. Hanke,et al.  Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[48]  Z. Kusic,et al.  Thyroglobulin determination, neck ultrasonography and iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[49]  F. Sundram,et al.  Evaluation of thyroid nodules for malignancy using 99Tcm‐sestamibi , 1995, Nuclear medicine communications.

[50]  T. Miyamoto,et al.  Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. , 1994, The Journal of clinical endocrinology and metabolism.

[51]  P. Ladenson,et al.  Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. , 1994, The Journal of clinical endocrinology and metabolism.

[52]  A. Avraham,et al.  Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[53]  F. Iida.  Thyroid Carcinoma , 1991, Pediatrics In Review.

[54]  L. Adler,et al.  Determination of malignancy of thyroid nodules with positron emission tomography. , 1993, Surgery.

[55]  B. van Eck-Smit,et al.  Comparison of serum thyroglobulin, 131I and 201Tl scintigraphy in the postoperative follow-up of differentiated thyroid cancer. , 1993, Nuclear medicine communications.

[56]  A. Ahuja,et al.  Role of ultrasound in the management of thyroid nodules. , 1992, American journal of surgery.

[57]  M. El-Desouki.  Tl-201 thyroid imaging in differentiating benign from malignant thyroid nodules. , 1991, Clinical nuclear medicine.

[58]  D. Appleton,et al.  THE SPECTRUM OF THYROID DISEASE IN A COMMUNITY: THE WHICKHAM SURVEY , 1977, Clinical endocrinology.

[59]  E. A. Gaston,et al.  The significance of nontoxic thyroid nodules. Final report of a 15-year study of the incidence of thyroid malignancy. , 1968, Annals of internal medicine.